XTL Biopharmaceuticals Ltd (H2K2) — Financial Flexibility Index
XTL Biopharmaceuticals Ltd (H2K2) has a Financial Flexibility Index of -0.50x as of December 2024. Free cash flow of €-1.56 Million (operating CF €-1.62 Million minus capex €54.00K) represents -1% of total liabilities (€3.12 Million). Also explore net asset growth rate of XTL Biopharmaceuticals Ltd to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
XTL Biopharmaceuticals Ltd Financial Flexibility Index (2016–2024)
Historical Financial Flexibility Index trend for XTL Biopharmaceuticals Ltd across 9 annual periods. Check H2K2 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for XTL Biopharmaceuticals Ltd (2016–2024)
Year-by-year free cash flow to debt coverage for XTL Biopharmaceuticals Ltd. For the full company profile including market capitalisation, see market value of XTL Biopharmaceuticals Ltd.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -0.50x | €-1.56 Million | €-1.62 Million | €3.12 Million | ▲ +85.4% |
| 2023 | -3.43x | €-707.00K | €-707.00K | €206.00K | ▲ +28.8% |
| 2022 | -4.82x | €-901.00K | €-901.00K | €187.00K | ▼ -490.2% |
| 2021 | -0.82x | €-1.05 Million | €-1.05 Million | €1.28 Million | ▲ +75.6% |
| 2020 | -3.34x | €-849.00K | €-850.00K | €254.00K | ▲ +14.4% |
| 2019 | -3.91x | €-906.00K | €-908.00K | €232.00K | ▼ -21.4% |
| 2018 | -3.22x | €-814.00K | €-816.00K | €253.00K | ▼ -750.0% |
| 2017 | -0.38x | €-1.12 Million | €-1.12 Million | €2.97 Million | ▲ +92.5% |
| 2016 | -5.05x | €-1.67 Million | €-1.73 Million | €330.00K | — |